Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis

NCT ID: NCT04792281

Last Updated: 2024-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

97 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General Hospital , the McGill University Health Centre and the CHUS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infective Endocarditis Native Valve Endocarditis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with suspected native valve endocarditis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older, capable to provide informed consent;
* Referred for a FDG-PET/CT study
* Classified as having Possible IE prior to FDG-PET/CT imaging;
* Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan.

Exclusion Criteria

* Subjects with prosthetic cardiac valve and/or CIED;
* Pregnant or breastfeeding female;
* Body mass index \> 45 kg/m2.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Montreal Heart Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Matthieu Pelletier-Galarneau, MD MSc

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, Canada

Site Status NOT_YET_RECRUITING

Montreal Heart Institute

Montreal, Quebec, Canada

Site Status RECRUITING

Jewish General Hospital

Montreal, Quebec, Canada

Site Status RECRUITING

McGill University Health Center

Montreal, Quebec, Canada

Site Status NOT_YET_RECRUITING

University Institute of Cardiology and Respirology of Quebec

Québec, Quebec, Canada

Site Status NOT_YET_RECRUITING

Centre Hospitalier de l'Universite de Sherbrooke

Sherbrooke, Quebec, Canada

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Daniel Juneau

Role: primary

Matthieu Pelletier-Galarneau

Role: primary

5143763330 ext. 4418

Gad Abikhzer

Role: primary

514-340-8222

Anthony Ciarallo

Role: primary

514-934-1934

Jean-Francois Sarrazin

Role: primary

Etienne Rousseau

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MP-33-2020-2674

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Belgian Infective Endocarditis Registry
NCT06745440 NOT_YET_RECRUITING